In Gilead Sciences, Inc. v. Apotex, Inc., No. 20-cv-189 (D. Del. May 26, 2021) Judge Noreika in the District Court of Delaware construed claim terms in Gilead’s patents, including in U.S. Pat. Nos. 8,754,065 (“the ‘065 patent) and 9,296,769 (“the ‘769 patent”). The ‘065 and ‘769 patents contain compound, composition, and method of making claims. Of interest to life science patent application drafters and prosecutors, evaluators of third party U.S. patents, AIA post-grant proceeding practitioners, and litigators is the court’s analysis of whether terms in the claims of those two patents are limited to salt forms and non-ionized/unassociated forms or whether a broader construction should apply.